NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
|ClinicalTrials.gov Identifier: NCT01370954|
Recruitment Status : Completed
First Posted : June 10, 2011
Last Update Posted : May 9, 2013
|Condition or disease||Intervention/treatment|
|Early Memory Loss Mild Cognitive Impairment Alzheimer's Disease Vascular Dementia||Other: CerefolinNAC®|
|Study Type :||Observational|
|Actual Enrollment :||204 participants|
|Official Title:||NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||December 2012|
Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
- To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD) [ Time Frame: Baseline, Week 6 and Week 12 ]The QOL-AD is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life.
- To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale [ Time Frame: Weeks 6 and 12 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01370954
|United States, North Carolina|
|Falls Neurology and Memory Center|
|Hickory, North Carolina, United States, 28601|
|Principal Investigator:||Donald E Schmechel, M.D.||Falls Neurology and Memory Center|